On July 31, Guardant Health Inc. rose 10.72% in regular trading, trading at $168.31/share, with turnover of $164 million. The surge was driven by the company's Q2 earnings release, which showed revenue significantly exceeding market expectations along with an upward revision to full-year guidance.

Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year and well above the analyst consensus estimate of $314.2 million. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier. The company raised its full-year 2026 revenue guidance to $1.34 billion–$1.36 billion, up from the prior range of $1.30 billion–$1.32 billion, surpassing the FactSet estimate of $1.31 billion.

The strong results were further supported by multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple cancer therapies, inclusion of its Shield blood test in American Cancer Society colorectal cancer screening guidelines, and target price increases from BofA Securities, RBC Capital Markets, and Evercore ISI.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)